Class Action Lawsuit Over EpiPen Pricing, Kickbacks Allowed to Proceed
Mylan must face a class action lawsuit over claims of price-fixing and bribery after a federal judge refused to dismiss their claims.
Mylan must face a class action lawsuit over claims of price-fixing and bribery after a federal judge refused to dismiss their claims.
The FDA warns that some generic EpiPens may deliver an overdose of epinephrine due to a missing component.
Mylan and the FDA warn that EpiPens may go off prematurely if they experience sideways pressure, and in some cases may become stuck in their carriers.
A new study indicates epinephrine use increased the risk of surviving cardiac arrest, but also appeared to increase the risk of neurologic damage among survivors.
The FDA received more than 200 reports of EpiPen failures this year by mid-September, including seven reports of consumer deaths, according to a Freedom of Information Act request.
The FDA has issued a warning letter to the manufacturers of the EpiPen, indicating that they ignored complaints of malfunctions and should have issued an EpiPen recall.
All EpiPen pricing lawsuits have been consolidated before one judge who will oversee pretrial proceedings and class action certification for claims that the company is unfairly dominating the epinephrine injector…
A new study reveals that most children who need an EpiPen injection due to a severe allergic reaction are not receiving them, resulting in longer hospital stays.
An EpiPen class action lawsuit claims Mylan illegally dominated the epinephrine injector market by paying illegal rebates to pharmacy benefit managers.
An EpiPen recall has been expanded to include injection devices sold in the U.S.